EMG
ADVM

Ellington Management Group’s Adverum Biotechnologies ADVM Stock Holding History

Ellington Management Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,240
Closed -$116K – 248
2016
Q1 		$116K Buy
+2,240
New +$125K 0.05% 459

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Ellington Management Group's ADVM Position: Q2 2016 in Review

Ellington Management Group sold out of Adverum Biotechnologies (ADVM) in Q2 2016, closing a stake of 2,240 shares — an estimated $116K sold.

Ellington Management Group first reported a position in ADVM in Q1 2016 and held it in 1 quarter. The position peaked at $116K in Q1 2016. 77 funds tracked by Wall St. Rank hold ADVM as of Q2 2016.

  • Ellington Management Group reported no remaining Adverum Biotechnologies position as of Q2 2016 after selling out during the quarter.
  • Ellington Management Group sold 2,240 Adverum Biotechnologies shares in Q2 2016, an estimated $116K.
  • Ellington Management Group first reported a position in Adverum Biotechnologies in Q1 2016 and held it in 1 quarter.
  • Ellington Management Group's Adverum Biotechnologies position peaked at $116K in Q1 2016.
  • 77 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2016.

Based on Ellington Management Group's 13F filing for Q2 2016, filed 15 Aug 2016.